Objective Most antineoplastic drugs are highly toxic and can cause drug‐related gastrointestinal reactions. This review aimed to critically appraise the impact of clinical pharmacists in reducing the intensity of nausea and vomiting following chemotherapy in cancer patients. Methods A search was conducted to retrieve studies from eight databases that assessed the extent of pharmacist intervention in relieving nausea and vomiting after chemotherapy in cancer patients from construction to February 2024. Results A total of 3077 records were retrieved, of which 20 met the inclusion criteria. The results demonstrated that the involvement of clinical pharmacists in the management of CINV in oncology patients was effective in increasing the rate of complete control of acute ( p < 0.001, RR = 1.21 1.11–1.32) and delayed ( p < 0.001, RR = 1.28 1.02–1.59) vomiting in chemotherapy patients. The incidence of nausea ( p < 0.001, RR = 0.77 0.69–0.85) and delayed nausea ( p < 0.001, RR = 0.67 0.53–0.85) in chemotherapy patients was also effectively mitigated. There was a significant improvement in patient adherence to oncology treatment ( p < 0.001, OR = 6.51 3.18–13.35). Conclusion Clinical pharmacists’ involvement in the management of CINV in patients undergoing cancer chemotherapy resulted in a reduction in the incidence of nausea and vomiting and improved patient adherence to treatment. The involvement of clinical pharmacists in the management of chemotherapy‐induced nausea and vomiting, either directly or as a key member of the multidisciplinary oncology team, is of significant importance.
Lin et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: